US5055301A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of dextran sulphate for the treatment of human prostatic carcinoma
Assignee: Entec Gesellschaft fuer Endokrinologische Technologie mbH
•
Filing: 1990-01-17
•
Granted: 1991-10-08
•
Expires: 2010-01-17
Abstract
Abstract The invention relates to the use of dextran sulphate, optionally in combination with anti-androgen agents, for the treatment of the human prostatic carcinoma. Inhibition of the growth of both androgen-dependent and androgen-independent carcinoma cells is achieved according to the invention. The invention therefore leads to a significant improvement in the possible therapies for human prostatic carcinoma.
Inventors
- 👤 Klaus-Dieter Voigt
- 👤 Cornelius Knabbe
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 22:50
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/185
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
41 words
A method of treating human prostatic carcinoma comprising administering to a patient having a human prostatic carcinoma susceptible to treatment a pharmaceutical composition consisting essentially of dextran sulfate in an amount effective to inhibit the proliferation of human prostatic carcinoma cells.
Claim 2
Independent Claim
41 words
A method of treating human prostatic carcinoma comprising administering to a patient having a human prostatic carcinoma susceptible to treatment a pharmaceutical composition consisting essentially of dextran sulfate in an amount effective to inhibit the proliferation of human prostatic carcinoma cells.
Claim 3
Dependent Claim
14 words
The method of claim 1, in which the carcinoma is androgen-independent human prostatic carcinoma.
Claim 4
Dependent Claim
21 words
The method of claim 1, in which the average molecular weight of the dextran sulphate is about 5,000 to about 500,000.
Claim 5
Dependent Claim
21 words
The method of claim 2, in which the average molecular weight of the dextran sulphate is about 5,000 to about 500,000.
Claim 6
Dependent Claim
27 words
The method of claim 1, in which the patient is administered about 2 to about 40 mg/kg/day dextran sulphate based upon the patient's body weight in kg.
Claim 7
Independent Claim
54 words
A method of treating human prostatic carcinoma in a patient having both androgen-dependent and androgen-independent human prostatic carcinoma comprising administering to the patient a pharmaceutical composition consisting essentially of, in combination amounts of both an anti-androgenic agent and dextran sulphate effective to inhibit the proliferation of both androgen-dependent and androgen-independent human prostatic carcinoma cells.
Claim 8
Independent Claim
54 words
A method of treating human prostatic carcinoma in a patient having both androgen-dependent and androgen-independent human prostatic carcinoma comprising administering to the patient a pharmaceutical composition consisting essentially of, in combination amounts of both an anti-androgenic agent and dextran sulphate effective to inhibit the proliferation of both androgen-dependent and androgen-independent human prostatic carcinoma cells.
Claim 9
Dependent Claim
21 words
The method of claim 6, in which the dextran sulphate and anti-androgenic agent are administered concurrently in the same pharmaceutical composition.
Claim 10
Dependent Claim
20 words
The method of claim 6, in which the average molecular weight of the dextran sulphate is about 5,000 to 500,000.
Claim 11
Dependent Claim
20 words
The method of claim 8, in which the average molecular weight of the dextran sulphate is about 5,000 to 60,000.
Claim 12
Dependent Claim
27 words
The method of claim 6, in which the patient is administered about 2 to about 40 mg/kg/day dextran sulphate based upon the patient's body weight in kg.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-10-07 | 1995-04-08 | 1995-10-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-10-07 | 1999-04-08 | 1999-10-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-10-07 | 2003-04-08 | 2003-10-08 | $7700.00 | Window Closed / Lapsed |